Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Revenue for the year ending December 31, 2023: USD 3.21 B

Jiangsu Hengrui Medicine Co., Ltd. Revenue is USD 3.21 B for the year ending December 31, 2023, a 4.25% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Jiangsu Hengrui Medicine Co., Ltd. Revenue for the year ending December 31, 2022 was USD 3.08 B, a -24.38% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Revenue for the year ending December 31, 2021 was USD 4.08 B, a -4.05% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Revenue for the year ending December 31, 2020 was USD 4.25 B, a 27.05% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Revenue for the year ending December 31, 2019 was USD 3.34 B, a 32.05% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years